Skip to main content

Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes

Buy Article:

$63.00 plus tax (Refund Policy)

During the development of new nonsteroidal anti-inflammatory agents, it was discovered that 1- aminoalkyl-3-aroylindoles have affinity for the cannabinoid brain (CB1) receptor. This has led to the development of over 100 cannabimimetic aminoalkylindoles, and the development of SAR for these compounds. Later work demonstrated that the aminoalkyl moiety was not necessary, and could be replaced by a four- to sixmembered alkyl chain without loss of affinity. Investigation of these indoles led to the discovery of a CB2 selective ligand, 3-(1-naphthoyl)-N-propylindole. Subsequent work has provided several additional CB2 selective indoles. On the basis of a proposed pharmacophore for the cannabimimetic indoles, a series of pyrroles and indenes were developed, some of which are potent cannabinoids. SAR for several series of pyrroles have been developed. Two groups have described cannabimimetic indenes, which have been employed as rigid models for the receptor interactions of cannabimimetic indoles with the CB1 receptor. There is some evidence that the indoles bind to a somewhat different site on the receptor than traditional cannabinoids, and interact with the receptor primarily by aromatic stacking.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: aminoalkylindole; cannabinoid; indene; indole; pyrrole; receptor

Document Type: Review Article

Affiliations: H. L. Hunter Chemistry Laboratory, Clemson University, Clemson, South Carolina 29634-0973, USA.

Publication date: 2005-06-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more